Selumetinib

• Post Date:

  Mar 24,2015

• Expiry Date:

  Apr 23,2015

• Detailed Description:

  Cas No. :606143-52-6 Quantity: 5mgFCL
  Price:30 USD FCL
  Payment Method: T/T, Western Union
  Introduction: Selumetinib, activating mutations in the BRAF gene, primarily at V600E, are associated with poorer outcomes in patients with papillary thyroid cancer.[clarification needed] MAPK kinase (MEK), immediately downstream of BRAF, is a promising target for MAPK/ERK pathway inhibition. In addition to thyroid cancer, BRAF-activating mutations are prevalent in melanoma (–59%), colorectal cancer (5–22%), serous ovarian cancer (–30%), and several other tumor types. Four lines bearing V600E BRAF mutations were all sensitive to selumetinib, with GI50 values ranging from 14 to 50 nM. A positive control BRAF mutant melanoma line, SKMel28, exhibited a similar GI50 of 23 nM. A Phase II clinical trial about selumetinib in cancers with BRAF mutations is ongoing.
  
  CAS Number: 606143-52-6
  Name: 1H-benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-
  Superlist Name: AZD 6244
  Formula: C17H15BrClFN4O3
  Molecular Weight: 457.68
  Synonyms: AZD 6244;5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide;
  Density: 1.692 g/cm3
  
  http://www.ncebiomed.com/product/productmain/1433.html

• CAS Registry Number:

  606143-52-6

• Synonyms:

  ;ZD-6244;ARRY-142886;AZD6244;5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide;AZD 6244;AZD-6224;5-(4-Bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzimidazole-6-carbohydroxamic acid 2-hydroxyethyl ester;

• Molecular Formula:

  C₁₇H₁₅BrClFN₄O₃

• Molecular Weight:

  457.6813

• Molecular Structure:

  

• Company:

  NCE Biomedical Co., Ltd     [ China ]        

• Contact:

  Donna

• Tel:

  +86-27-87599188

• Fax:

  +86 27-87599188

• Email:

  sales@ncebiomed.com